MedPath

Capsaicin

Generic Name
Capsaicin
Brand Names
Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix
Drug Type
Small Molecule
Chemical Formula
C18H27NO3
CAS Number
404-86-4
Unique Ingredient Identifier
S07O44R1ZM
Background

Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Indication

The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions
Back Pain Lower Back, Back pain, Bursitis, Contusions, Inflammatory Reaction caused by Rheumatism, Muscle Cramps, Musculoskeletal Pain, Neuropathic Pain, Osteoarthritis (OA), Pain caused by Rheumatism, Periarthritis, Soft Tissue Injury, Tendinitis, Acute nonspecific tenosynovitis, Articular inflammation
Clinical Trials
Related News

Airway Protective Mechanisms in PD (R01)

Completed
Conditions
Parkinson Disease
Interventions
Device: Resistive respiratory loads
Other: Event-related evoked potential using electroencephalography (EEG).
Procedure: Fluoroscopic swallow evaluation
First Posted Date
2017-10-25
Last Posted Date
2024-10-10
Lead Sponsor
University of Florida
Target Recruit Count
119
Registration Number
NCT03321019
Locations
🇺🇸

University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida, United States

Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

Phase 2
Completed
Conditions
Neuropathic Pain
Interventions
First Posted Date
2017-10-23
Last Posted Date
2022-02-08
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
84
Registration Number
NCT03317613
Locations
🇫🇷

Centre Jean Perrin, Clermont-Ferrand, France

🇫🇷

Centre Hospitalier Emile Roux, Le Puy-en-Velay, France

🇫🇷

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France

Topical Capsaicin for Cyclical Vomiting

Phase 2
Completed
Conditions
Cyclical Vomiting
Interventions
Drug: Placebos
First Posted Date
2017-07-21
Last Posted Date
2021-12-15
Lead Sponsor
Henry Ford Health System
Target Recruit Count
30
Registration Number
NCT03223350
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

Capsaicin Patches In Knee Osteoarthritis In Obese Patients

Phase 3
Terminated
Conditions
Pain
Interventions
Other: Placebo patches
First Posted Date
2017-05-15
Last Posted Date
2019-04-17
Lead Sponsor
Nadine ATTAL
Target Recruit Count
22
Registration Number
NCT03153813
Locations
🇫🇷

Hospital Ambroise Paré, Nutrition Department, Boulogne-Billancourt, France

Ibuprofen Gel or Capsaicin Cream for my Painful Knee Osteoarthritis?

Not Applicable
Completed
Conditions
Osteoarthritis, Knee
Interventions
Drug: Topical NSAID
First Posted Date
2017-05-10
Last Posted Date
2019-04-18
Lead Sponsor
University of Nottingham
Target Recruit Count
22
Registration Number
NCT03146689
Locations
🇬🇧

Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom

Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol

Not Applicable
Conditions
Pain
Pruritus
Dermatology/Skin - Other
Neuropathic Pain
Interventions
Drug: Vehicle patch
First Posted Date
2017-04-27
Last Posted Date
2017-04-27
Lead Sponsor
Aalborg University
Target Recruit Count
22
Registration Number
NCT03132142
Locations
🇩🇰

SMI, Aalborg, Denmark

Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200

Phase 4
Completed
Conditions
Osteoarthritis, Knee
Interventions
Other: Drug product vehicle
First Posted Date
2017-04-21
Last Posted Date
2024-10-31
Lead Sponsor
Propella Therapeutics
Target Recruit Count
120
Registration Number
NCT03124407
Locations
🇺🇸

Research Center, Dallas, Texas, United States

Normal Breathing and Swallowing in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Device: Videofluoroscopic swallow study
First Posted Date
2017-04-20
Last Posted Date
2021-01-14
Lead Sponsor
University of Florida
Target Recruit Count
49
Registration Number
NCT03122145
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Delineating Swallowing Impairment and Decline in ALS

Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Procedure: Videofluoroscopic Swallowing Study (VFSS)
Device: Voluntary Peak Cough Flow Testing
Device: Iowa Oral Performance Instrument
Device: Pulmonary Function Testing
Other: Eating Assessment Tool 10
Other: The Center for Neurologic Study Bulbar Function Scale
First Posted Date
2016-11-11
Last Posted Date
2023-02-23
Lead Sponsor
University of Florida
Target Recruit Count
109
Registration Number
NCT02962050
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

Effect of Muscular Exercise on Cough Reflex

Not Applicable
Completed
Conditions
Cough
Interventions
Behavioral: Exercise
Drug: Normal saline
First Posted Date
2016-08-30
Last Posted Date
2016-08-30
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
60
Registration Number
NCT02882555
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy